MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.79
+4.36
+304.90%
After Hours: 5.07 -0.72 -12.44% 19:59 03/05 EST
OPEN
2.290
PREV CLOSE
1.430
HIGH
9.89
LOW
2.070
VOLUME
739.73M
TURNOVER
--
52 WEEK HIGH
9.89
52 WEEK LOW
0.6906
MARKET CAP
134.41M
P/E (TTM)
-4.4755
1D
5D
1M
3M
1Y
5Y
DJ Second Sight Medical Shares Hit 52-Week High on FDA Approval for Argus 2s
Dow Jones · 1d ago
Hot Reddit Penny Stocks For Your Watch List In March 2021
Mar 05, 2021 (Penny Stocks via COMTEX) -- Reddit Penny Stocks Continue Surging But Are They Worth The Risk? The stock market continues selling off today and...
Penny Stocks · 1d ago
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 1d ago
EYES Stock: The Big FDA News That Has Second Sight Shares Soaring
Second Sight (NASDAQ:EYES) stock is soaring higher Friday after announcing approval from the U.S. Food and Drug Administration (FDA) for its Argus 2s Retinal Prosthesis System. Source: Shutterstock Second Sight notes that the Argus 2s Retinal Prosthesis Sy...
InvestorPlace · 1d ago
Second Sight Medical Products, XTL Biopharmaceuticals leads healthcare gainers; Evofem Biosciences, T2 Biosystems among major losers
Gainers: Second Sight Medical Products (EYES) +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences (EVFM) -34%, T2 Biosystems (TTOO) -25%, IM...
Seekingalpha · 1d ago
DJ Second Sight Medical Products Shares Triple After FDA Approval
Dow Jones · 1d ago
Sector Update: Health Care
MT Newswires · 2d ago
DJ Second Sight Medical Gets FDA Approval for Argus 2s System
Dow Jones · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYES. Analyze the recent business situations of Second Sight Med through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 1.70M
% Owned: 7.31%
Shares Outstanding: 23.21M
TypeInstitutionsShares
Increased
7
320.40K
New
12
-480.08K
Decreased
2
94.32K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.73%
Healthcare Equipment & Supplies
+2.13%
Key Executives
Chairman/Director
Gregg Williams
Chief Executive Officer/Director
Matthew Pfeffer
Vice President - Operations
Ted Randolph
Vice President
Edward Randolph
Other
Stephen Okland
Director
Jonathan McGuire
Independent Director
Aaron Mendelsohn
No Data
  • All
  • Financials
  • Insiders
More
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.